Estimating a Preference-Based Single Index From the Overactive Bladder Questionnaire

Yang, Yingchi; Brazier, John; Tsuchiya, Akane; Young, T.K.; Coyneb, K.

doi:10.1016/s1569-9056(06)60834-8

Cited by 15 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, six measures involved the derivation of the classification system from an existing measure using psychometric criteria, elicited health states from the general population and used statistical modelling with an additive function to produce utility values for all states anchored on to a 0-1 dead-full health scale. 23,[30][31][32][33][50][51][52] However, even across these studies there are differences in the methodology used, including the psychometric criteria used to obtain the classification for stages I-III, and valuation technique and selection of health states for valuation for stage V.…”

Section: Discussionmentioning

confidence: 99%

“…Stages of developing preference-based measure Stages I-III: deriving the classification system Three papers reported only the valuation component 30,54,59 of deriving a measure and hence are not discussed in this section, as the derivation of the classification systems was undertaken in separate papers. 31,53,58 Derivation of classification system from existing measure Fourteen papers reported on measures that derived the classification system for the preferencebased measure from an existing measure of HRQoL.…”

Section: Conditionsmentioning

confidence: 99%

See 1 more Smart Citation

Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).

Brazier

Rowen²,

Mavranezouli³

et al. 2012

Health Technol Assess

155

219

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are ...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Conditionsmentioning

confidence: 99%

Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).

Brazier

Rowen²,

Mavranezouli³

et al. 2012

Health Technol Assess

155

219

View full text Add to dashboard Cite

show abstract

“…[9][10][11][12][13] Time trade-off is an iterative cardinal technique that elicits a health-state value by asking respondents to trade off time in full health to avoid living in a hypothetical health state described by the classification system. The value is derived at the point where respondents are indifferent between the scenarios.…”

Section: Methods Of Health-state Valuation Considered In Pret Ttomentioning

confidence: 99%

“…The value sets for the three-level EQ-5D, 3 and SF-6D, 23,24 generic preference-based measures of health and a range of condition-specific measures [9][10][11][12][13] are based on general population values, and this is recommended by NICE. 2 However, it is possible that the values given to hypothetical health states by the general population may differ from values given by patients, and there has been debate about whose values should be used.…”

Section: Whose Values?mentioning

confidence: 99%

Preparatory study for the revaluation of the EQ-5D tariff: methodology report

Mulhern

Bansback

Brazier

et al. 2014

Health Technology Assessment

View full text Add to dashboard Cite

“…Health state utility values were derived from the EQ-5D index scores (based on the U.K. time trade-off tariff 45 ) and OAB-q, a five-dimensional health classification system derived from the validated Overactive Bladder Questionnaire (OAB-q), 46 which were collected as part of the SCORPIO study 29,30 using a mapping algorithm. Health state utilities according to symptom severity were derived by applying a linear regression model to the EQ-5D and OAB-5D scores, with adjustment for age, gender, and country.…”

Section: Health State Utilities Resource Use and Costsmentioning

confidence: 99%

Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada

Herschorn¹,

Nazir²,

Ramos³

et al. 2017

CUAJ

View full text Add to dashboard Cite

Introduction: This analysis compared the cost-effectiveness of once-daily regimens of mirabegron 50 mg and generic tolterodine ER 4 mg in a hypothetical cohort of previously treated patients with overactive bladder (OAB) in Canada. Methods: A Markov model was developed to represent different health states according to OAB symptoms (frequency, incontinence), presence/absence of adverse events (AEs; dry mouth, constipation, blurred vision), and treatment status (on-treatment, discontinue treatment, restart previous treatment). The time horizon used was one year, with monthly transitions between health states. The model was populated using data from a phase 3, placebo-controlled trial of mirabegron that included tolterodine as an active comparator (SCORPIO), as well as other published literature and expert opinion. Cost-effectiveness was calculated from Canadian public payer (based on Quebec list prices) and societal perspectives. Results: The incremental one-year cost per patient for mirabegron over tolterodine was $182 CAD and $157 CAD from the payer and societal perspectives, respectively. The incremental quality-adjusted life year (QALY) gain for mirabegron was 0.0066 when using EQ-5D health-state utilities. Mirabegron was cost-effective compared with tolterodine, from both payer and societal perspectives, and remained cost-effective vs. tolterodine across the majority of sensitivity analyses. The model was based on limited clinical trial evidence supplemented with expert opinion and assumptions; a select number of OAB symptoms, AEs, and direct and indirect medical costs associated with OAB; and a timeframe of only one year. Conclusions: From the payer and societal perspectives, the health economic model indicates that in Canada, mirabegron is a cost-effective treatment strategy compared with tolterodine, leading to improved health outcomes (QALYs) at an acceptable incremental cost. IntroductionOveractive bladder (OAB) is a bothersome condition with a relatively high prevalence in the general population. In a survey of over 16 500 subjects aged ≥40 years in six European countries, the prevalence of OAB was 16.6%.1 In a subsequent survey of over 19 000 subjects aged ≥18 years in Canada and Europe, the prevalence of OAB was 11.8%. OAB has a substantial negative impact on patients' health-related quality of life (HRQoL) and mental health. 5The cardinal symptoms -urgency with or without incontinence, usually associated with frequency, and nocturia 6 -interfere with basic activities of daily living, such as work, travel, sleep, interpersonal activities, sexual function, and physical activities. 7,8 Studies have often focused specifically on the impact of incontinence, but it has been shown that frequency and urgency, which are more prevalent, are as bothersome as urgency incontinence.1 In terms of mental health, it is estimated that approximately one-third of men and women with lower urinary tract symptoms may have comorbid clinical anxiety and/or depression. 9 In addition, it has been shown that the prevale...

show abstract

Estimating a Preference-Based Single Index From the Overactive Bladder Questionnaire

Cited by 15 publications

References 0 publications

Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).

Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).

Preparatory study for the revaluation of the EQ-5D tariff: methodology report

Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada

Contact Info

Product

Resources

About